Case Study: Biotech IP Valuation Case Study: Pricing a Phase 2 Oncology Patent

A biotech IP valuation case study has to price something most valuation models quietly ignore: the chance the asset never reaches the market at all. In drug development the patent is the company, and that patent sits on top of a molecule whose cash flows are both enormous and probabilistic. This representative engagement shows how PerspireIP valued the lead patent family of a clinical-stage oncology biotech ahead of a partnering-and-financing decision, using risk-adjusted net present value (rNPV) as the primary method, a relief-from-royalty cross-check as the reality test, and the expiry of a single composition-of-matter claim as the hard ceiling on everything else.

The Challenge

A clinical-stage oncology biotech came to us ahead of two decisions that turned on the same number: a Series C raise, and a term sheet from a larger pharma company offering an upfront payment, development milestones and a royalty on net sales. Both counterparties were pricing the company off one lead asset — a small-molecule candidate about to read out Phase 2 data — and the company’s own board could not agree on what that asset, and the patents protecting it, were actually worth. A number that was too low would give away the upside in a partnering deal; a number that was too high would not survive an investor’s own model.

The honest difficulty is that a drug patent is worth a probability-weighted bet, not a fixed cash flow. The industry benchmark for how long that bet runs is sobering. In the BIO, Informa Pharma Intelligence and QLS Advisors study of clinical development from 2011 to 2020 — 12,728 phase transitions — only 7.9% of drugs entering Phase I went on to FDA approval. In oncology the figure is worse: a 5.3% likelihood of approval from Phase I across 4,179 oncology transitions, against 9.3% for non-oncology indications. A valuation that treats a Phase 2 oncology candidate as if it will certainly launch is not optimistic; it is wrong by more than an order of magnitude.

The second difficulty was that the client treated “the patent portfolio” as one thing. It was not. The family contained a composition-of-matter patent on the molecule, a later formulation patent, and a method-of-use patent on the specific indication — three claims with three different expiry dates, protecting three different slices of the cash flow. Pricing the asset meant deciding which patent actually carries the revenue, and for how long, because in pharmaceuticals the terminal value is set by the patent cliff, not by peak sales.

How We Ran the Biotech IP Valuation Case Study in Four Stages

We ran this biotech IP valuation case study the way the standard of value demands: define the question first, then let the method follow it. For a partnering-and-financing decision the relevant standard is fair market value of the patent-backed asset, so the model had to be defensible to a sophisticated counterparty’s own analysts, not merely internally tidy.

• Map each patent to the cash flow it actually protects. We separated the family into the composition-of-matter claim (which protects the molecule itself, and therefore the core revenue annuity), the formulation claim, and the method-of-use claim, and dated each one including any available patent-term extension. The composition-of-matter expiry, net of extension, became the hard end of the forecast — everything after it is generic-eroded.
• Build the income approach as a risk-adjusted NPV. rNPV is the accepted framework for clinical-stage assets precisely because it separates the two things a naive DCF conflates: the size of the cash flow if the drug launches, and the probability it ever does. We forecast peak sales and uptake, then weighted the cash flows at each development gate by the phase-specific probabilities of success from the BIO data, and discounted the result.
• Cross-check with the market via relief-from-royalty. Independently of the income model, we estimated what the company would pay to license a comparable asset at the same stage, using published licensing-deal structures — upfront, milestones and a running royalty that rises steeply with each successful phase — so the rNPV was validated against real transactions, not just against itself.
• Stress-test with scenario and sensitivity analysis. We ran the valuation across a defensible range of discount rates, probabilities of success and patent-term assumptions, because for a pre-readout asset the point estimate matters far less than the shape of the distribution the board and investors are being asked to accept.

The sequencing is deliberate. An income model built before the patent boundaries are drawn will cheerfully discount cash flows the company has no right to collect; a market cross-check run without a clinical-risk adjustment will anchor on headline deal values that are mostly contingent. Doing both, in order, is what makes a biotech valuation survive diligence.

What the Research Found

The first finding reframed the entire negotiation: the value was concentrated in the composition-of-matter patent, and it ended when that patent did. The formulation and method-of-use claims added genuine option value — a potential lifecycle extension, a second indication — but neither extended the core revenue annuity in the way the client had assumed. In pharmaceuticals, loss of exclusivity is not a gentle decline: generic entry typically strips the great majority of a brand’s revenue within roughly a year, so the terminal value sat at the composition-of-matter cliff, not at some long tail of residual sales.

The second finding was that one clinical gate dominated the number. On the BIO 2011–2020 data, the Phase II to Phase III transition is the hardest step in all of drug development, with a success rate of just 28.9% across the industry. Because the asset was sitting immediately before that gate, the rNPV was acutely sensitive to it: clearing Phase 2 does not nudge the valuation, it re-rates the asset, which is exactly why the partnering counterparty wanted to sign before the readout and the company wanted to wait until after it.

The third finding was about discount rates. Biotech practitioners price early-stage risk far higher than a textbook WACC suggests — a survey of 242 life-science valuation professionals reported average discount rates of roughly 40% for early-stage, 27% for mid-stage and 20% for late-stage programmes. Applied correctly, that means part of the clinical risk can be captured in the probability weights and part in the discount rate, but not both at full strength, or the asset is double-penalised. Separating the two was the difference between a credible range and a number no investor would accept.

The Outcome

The deliverable was a valuation the company could defend on both sides of the table. Every figure below is a scenario value illustrating the shape of the work, not a measured result for a named client.

• A fair-market-value range for the patent-backed asset, stated as a distribution across probability of success, discount rate and patent term rather than a single false-precision figure.
• A clear statement that the composition-of-matter patent, net of any term extension, set the terminal value — which made a patent-term-extension filing the single highest-leverage IP action available, worth more than any additional late-stage claim.
• A relief-from-royalty cross-check that translated the rNPV into the language of the term sheet, so the board could compare a running royalty against an equity-equivalent value on a like-for-like basis.
• A readout-timing analysis quantifying how much the Phase II→III gate would move the number, so the company could decide whether to partner before or after the data with eyes open.
• A valuation memo and model that the Series C lead investor’s analysts, and the partner’s business-development team, could audit assumption by assumption.

With that in hand, the client stopped arguing about a single number and started negotiating a structure — upfront, milestones and royalty — against a shared, evidenced view of what each slice was worth and when the value would arrive.

What This Means for Similar Matters

The lesson that travels beyond this matter is that in biotechnology the patent is the asset, so a biotech IP valuation case study is really a question about two dates and one probability: when the composition-of-matter claim expires, when the drug might launch, and the odds it clears the next clinical gate. Get those three right and the valuation is defensible; get the patent boundaries wrong and the most elegant rNPV in the world is discounting money the company will never be entitled to.

The second lesson is methodological. rNPV beats a naive DCF for clinical-stage assets precisely because it forces the analyst to state the probability of success explicitly, where everyone can see and argue about it, rather than burying all of the clinical risk inside a single heroic discount rate. The discipline of pulling risk out into the open — and cross-checking it against what the market actually pays for comparable assets — is what separates a valuation that closes a deal from one that merely decorates a pitch deck.

Why the Patent Cliff, Not Peak Sales, Sets a Drug Patent’s Value

Founders and even experienced boards tend to anchor a drug’s value on peak annual sales, because that is the headline number in every analyst note. But a patent is a right to exclude for a fixed term, and the moment that term ends the economics invert. Once the composition-of-matter patent expires and generics enter, the overwhelming majority of brand revenue disappears quickly — so the value of the patent is the area under the curve before the cliff, not the height of the curve at its peak.

This is why, in our model, a patent-term extension was worth more than an additional late-filed claim: extending the core annuity by even a year at peak is worth far more than adding a narrow claim that generics can simply design around after launch. It is also why valuing a biotech asset without first mapping the patent family to its cash flows — the discipline behind our IP valuation service — produces numbers that look rigorous and are quietly meaningless. The same logic drives our patent valuation methods guide and the related how to value a drug patent walkthrough.

Data Sources

The market and patent data referenced above comes from:

• BIO, Informa Pharma Intelligence & QLS Advisors — Clinical Development Success Rates 2011–2020 — 12,728 phase transitions: 7.9% overall likelihood of approval from Phase I, 5.3% for oncology, and a 28.9% Phase II→III success rate.
• WIPO — Intellectual Property Valuation in Biotechnology and Pharmaceuticals — WIPO primer on the income, market and cost approaches as applied to life-science IP.
• Alacrita — Valuing Pharmaceutical Assets: When to Use NPV vs rNPV — Why risk-adjusted NPV is the standard for clinical-stage assets and how probability weighting interacts with the discount rate.
• Venture Valuation — Licensing Deal Trends and Valuation — Structure of life-science licensing deals — upfront, milestones and running royalties that rise with each successful phase — used for the relief-from-royalty cross-check.

Discuss a Similar Matter

Related PerspireIP work: IP valuation service · AI patent portfolio valuation case study · 5G SEP portfolio valuation case study · patent valuation methods guide.

Frequently Asked Questions